Treatment of cytomegalovirus infection

Details Treatment of cytomegalovirus infection Treatment of cytomegalovirus infection

1994-10-31

1997-05-27

Russel, Jeffrey E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 2, 514 14, 514 16, 514 17, 530327, 530328, 530329, 930 21, 930290, A61K 3803, A61K 3808, A61K 3810, C07K 706

Patent

active

056332300

ABSTRACT:
Described herein are anti-cytomegalovirus peptides. In a preferred embodiment, the peptide is acetyl-[D-Arg].sub.9 -NH.sub.2. The use of these peptides, either per se or in combination with other anti-CMV compounds, is disclosed as an effective method for controlling CMV infection.

REFERENCES:
patent: 4447356 (1984-05-01), Olivera
patent: 4782966 (1988-11-01), Thackrey
patent: 4837304 (1989-06-01), Garsky et al.
patent: 4845195 (1989-07-01), Colonno et al.
patent: 4923802 (1990-05-01), Gallis
patent: 5093317 (1992-03-01), Lewis
patent: 5171838 (1992-12-01), Chiba
Elion "Mechanism of Action and Selectivity of Acyclovir", The American Journal of Medicine, pp. 7-13 (1982).
Frankel et al. "Activity of Synthetic Peptides from the TAT Protein of Human Immunodeficiency Virus Type 1", Proc. Natl. Acad. Sci. USA 86, pp. 7397-7401 (1989).
Frankel et al. "Cellular Uptake of the TAT Protein from Human Immunodeficiency Virus", Cell, 55:1189-1193 (1988).
Geisow et al. "pH in the Endosome: Measurements During Pinocytosis and Receptor-Mediated Endocytosis", Experimental Cell Research 150, pp. 36-46 (1984).
Green et al. "Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus TAT Trans-Activator Protein", Cell, 55:1179-1188 (1988).
Green et al. "Mutational Analysis of HIV-1 TAT Minimal Domain Peptides: Identification of Trans-Dominant Mutants that Suppress HIV-LTR-Driven Gene Expression", Cell, 58:215-223 (1989).
Hauber et al. "Mutational Analysis of the Conserved Basic Domain of Human Immunodeficiency Virus TAT Protein", Journal of Virology, pp. 1181-1187 (1989).
Katsu et al. "Dissipation of Membrane Potential of Escherichia coli Cells Induced by Macromolecular Polylysine", Biochemical and Biophysical Research Communications, 122:401-406 (1984).
Kuppuswamy et al. "Multiple Functional Domains of TAT, the Trans-Activator of HIV-1, Defined by Mutational Analysis", Nucleic Acids Research, 17(9):3551-3559 (1989).
Morad et al. "Binding Sites and Endocytosis of Heparin and Polylysine are Changed When the Two Molecules are Given . . . ", Biochimica et Biophysica Acta, 801:117-126 (1984).
Nahata "Antiviral Drugs: Pharmacokinetics, Adverse Effects, and Therapeutic Use", Journal of Pharmacy Technology, pp. 100-108 (1987).
Pistocchi et al. "Transport and Subcellular Localization of Polyamines in Carr Protoplasts and Vacuoles", Plant Physiol, 87:514-518 (1988).
Ratner et al. "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III", Nature, 313:277-284 (1985).
Roy et al. "A Bulge Structure in HIV-1 TAR RNA is Required for TAT Binding and TAT-Mediated Trans-Activation", Genes and Development, 4:1365-1373 (1990).
Ruben et al. "Structural and Functional Characterization of Human Immunodeficiency Virus TAT Protein", Journal of Virology, pp. 1-8 (1989).
Ryser et al. "Methotrexate-Poly(Lysine) as a Selective Agent for Mutants of Chinese Hamster Ovary Cells Defective in Endocytosis", Journal of Cellular Physiology, 135:277-284 (1988).
Wagner et al. "Fibronectin-Coated Beads are Endocytosed by Cells and Align with Microfilament Bundles", Experimental Cell Research, 140:373-381 (1982).
Weeks et al. "Fragments of the HIV-1 TAT Protein Specifically Bind TAR RNA", Science, 249:1281-1285 (1990).
Docherty "Inactivation of Herpes Simplex Virus . . . ", Antimicrob. Agents Chemotherapy, 31(10):1562-6 (1987).
Webster et al, eds., Encyclopedia of Virology, vol. 1, published 1994 by Academic Press (San Diego), pp. 297-298.
Wyngaarden et al, eds., Cecil Textbook of Medicine, 19th ed., published 1992 by W. B. Saunders Co. (Phil.), p. 1837.

Affiliated with

Also associated with

Rating

Treatment of cytomegalovirus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of cytomegalovirus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cytomegalovirus infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2329077